AI may reshape psychiatry and clinical trials, but raises safety, regulation, and trust concerns.
Hans Eriksson, MD, PhD
Advertisement
Articles by Hans Eriksson, MD, PhD
Data show fast-acting psychedelic therapy for depression with lasting gains—plus the safety questions shaping its future.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression
2
Suicide Risk Assessment in Patients Denying Suicidal Intent
3
Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD
4